REG - Oxford Biomedica PLC - Board Changes

Oxford BioMedicaAnnouncement

18/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241118:nRSR5818Ma&default-theme=true

RNS Number : 5818M  Oxford Biomedica PLC  18 November 2024

 

Board Changes

-     Appointment of Colin Bond, a highly experienced Board member and
Audit Committee Chair with extensive international CDMO and biopharma
expertise

-     Appointment made as part of OXB's Board succession planning

Oxford, UK - 18 November 2024: OXB (LSE: OXB), a quality and innovation-led
cell and gene therapy CDMO, today announces the appointment of Colin Bond as a
Non-Executive Director effective 1 January 2025. Mr. Bond will also join the
Audit Committee as part of succession planning ahead of Stuart Henderson
losing his independent status as a Non-Executive Director in June 2025.

Colin Bond has a wealth of international experience in the CDMO and biopharma
industries and was most recently Chief Financial Officer of Sandoz listed on
the SIX Swiss Exchange, where he played a key role in the company's successful
spin-off from Novartis. Prior to Sandoz, Mr. Bond was Chief Financial Officer
of Vifor Pharma and Evotec. He also served as Chair of the Audit Committee
for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange, for ten
years until May 2023. He is currently Chair of the Audit Committee
of BioPharma Credit PLC on the London Stock Exchange and a member of
the Supervisory Board of Formycon AG.

During his early career, Mr. Bond worked as a pharmacist, auditor and
management consultant for Procter & Gamble, Arthur Andersen and PwC. Mr.
Bond is a Fellow of the Institute of Chartered Accountants in England and
Wales and a Member of the Royal Pharmaceutical Society of Great Britain. He
holds a BSc in Pharmacy from Aston University and an MBA from London Business
School.

Additionally, OXB announces that Leone Patterson has informed the Board of her
decision to step down as a Non-Executive Director on 31 December 2024 in order
to focus on her new responsibilities following her recent appointment as Chief
Business and Financial Officer of Zymeworks.

Dr. Roch Doliveux, Chair of OXB, commented: "Colin is a highly strategic
operator with extensive international CDMO and healthcare sector expertise
plus first-rate technical accounting credentials. He is well regarded by the
investment community and has overseen organisations that have undergone
significant growth and transformation. On behalf of the Board, I am delighted
to welcome Colin to OXB and thoroughly look forward to working with him. I
would also like to thank Leone for her sharp analytical insights and active
contributions to OXB during her tenure on the Board and wish her the very best
with her new responsibilities."

Colin Bond, incoming Board member at OXB, said: "OXB's position as a leader in
cell and gene therapy manufacturing, combined with its innovative approach and
strong client partnerships, presents a compelling opportunity that I have
recently watched with interest. I am excited to join the Board at this
important time and look forward to working with the team to support OXB's
continued growth and success in enabling the delivery of life-changing
therapies to patients worldwide."

Relevant disclosures

Save as disclosed, there are no disclosures required to be made in accordance
with UKLR 6.4.8(R).

 

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class capabilities
span from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFFLFWWELSEIF